Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2020
A new biosimilar to NovoRapid is included in the high-cost protection
28 August 2020 - Insulin aspart Sanofi (insulin aspart) solution for injection for the treatment of diabetes is included in ...
Posted by Michael Wonder on 27 Aug 2020
Mylan, Lupin launch etanercept biosimilar in Germany
26 August 2020 - The launch marks the first European market entry for Nepexto. ...
Posted by Michael Wonder on 21 Aug 2020
Samsung Bioepis receives European Commission approval for Aynbintio (bevacizumab)
20 August 2020 - Aybintio is Samsung Bioepis’ fifth biosimilar to be approved by the European Commission. ...
Posted by Michael Wonder on 19 Aug 2020
Launch of two biosimilars
19 August 2020 - Sandoz Canada announces an agreement with the pCPA and the launches of Ziextenzo and Riximyo. ...
Posted by Michael Wonder on 18 Aug 2020
China's first trastuzumab biosimilar approved by NMPA
17 August 2020 - Shanghai Henlius Biotech announced on 14 August that the trastuzumab biosimilar HLX02, developed and manufactured by Henlius ...
Posted by Michael Wonder on 17 Aug 2020
Irish pharmacists lobby for biosimilar substitution
17 August 2020 - Pharmacists in Ireland say the country is losing out on hundreds of millions of dollars in savings ...
Posted by Michael Wonder on 13 Aug 2020
Disney official, others, talk about switch to biosimilars
12 August 2020 - Dismayed at the low biosimilar uptake and the lost savings, large employers are taking matters into their ...
Posted by Michael Wonder on 03 Aug 2020
Slow start for infliximab biosimilars
3 August 2020 - Investigators speculate on why infliximab biosimilars don’t have a larger market share by now. ...
Posted by Michael Wonder on 30 Jul 2020
Henlius and Accord Healthcare receive EMA approval for Zercepac, trastuzumab biosimilar
29 July 2020 - The European Commission has approved Shanghai Henlius Biotech and Accord Healthcare's Zercepac, a biosimilar trastuzumab, for ...
Posted by Michael Wonder on 28 Jul 2020
European Commission grants marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima SC, for an additional five indications including for use in inflammatory bowel disease and ankylosing spondylitis
27July 2020 - The EU marketing authorisation is based on pivotal data comparing the pharmacokinetics, efficacy and safety of the intravenous ...
Posted by Michael Wonder on 27 Jul 2020
Biosimilar insulin glargine on the PBS - information for health professionals and patients
27 July 2020 - Changes have been made from 1 July 2020 to the PBS listings for insulin glargine, as the ...
Posted by Michael Wonder on 18 Jul 2020
Why biosimilar approval applications break down
17 July 2020 - Investigators found that process complexities have created numerous difficulties for biosimilar developers in regulatory filings, but ...
Posted by Michael Wonder on 14 Jul 2020
Biosimilar Awareness Week proves successful for Australia
13 July 2020 - The Generic and Biosimilar Medicines Association in Australia reported its 2020 Biosimilar Awareness Week was successful, with ...
Posted by Michael Wonder on 09 Jul 2020
Mylan and Fujifilm Kyowa Kirin Biologics announce U.S. FDA approval of Hulio (adalimumab-fkjp)
9 July 2020 - Mylan and Fujifilm Kyowa Kirin Biologics today announced that the U.S. FDA has approved Hulio (adalimumab-fkjp), ...
Posted by Michael Wonder on 07 Jul 2020
Remove the disincentives and biosimilars will flourish, policy expert says
7 July 2020 - Patients could save as much as 17% on out-of-pocket costs if they used biosimilars, but many ...